How to Get Dayvigo (Lemborexant) in Michigan

What Is Dayvigo and Why Does It Work Differently From Older Sleep Aids

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R receptors, the two receptors responsible for the wake-promoting signal produced by orexin peptides in the lateral hypothalamus. By silencing that wake signal rather than globally depressing the central nervous system, lemborexant produces sleep without the next-morning motor and cognitive impairment associated with benzodiazepines and Z-drugs at comparable doses. 1

The FDA approved lemborexant on December 20, 2019, for adults with insomnia characterized by difficulty falling asleep, difficulty staying asleep, or both. 2 The mechanism is meaningfully different from older agents: benzodiazepines and Z-drugs act on GABA-A receptors, while DORAs work by competitive antagonism of orexin neuropeptides. The shift in mechanism translates to a different side-effect profile and, in comparative trials, a lower rate of residual sedation. 3

SUNRISE-1 (N=291, published JAMA Network Open 2019) demonstrated that lemborexant 5 mg and 10 mg both significantly reduced sleep-onset latency and waking after sleep onset compared with placebo over 30 nights. Lemborexant 10 mg also outperformed zolpidem tartrate extended-release 6.25 mg on objective sleep-onset latency on night 1 (P<0.05) and maintained that advantage through the end of the study. 4

The SUNRISE-2 trial (N=949 to 12 months) confirmed sustained efficacy without rebound insomnia or withdrawal symptoms upon discontinuation, a property the FDA's approval language specifically highlights. 5

Who Can Prescribe Dayvigo in Michigan

Any Michigan-licensed prescriber with Schedule IV DEA registration may write a lemborexant prescription. That group includes physicians (MD or DO), nurse practitioners with full prescriptive authority under Michigan Public Act 57 of 2017, and physician assistants with a supervision agreement that covers controlled substances. 6

Psychiatrists and sleep medicine physicians prescribe Dayvigo most frequently, but primary care clinicians, internal medicine physicians, and certain nurse practitioners in Michigan write the majority of insomnia prescriptions overall. A sleep-specialist referral is not required by Michigan law, though some insurance plans request a sleep study or sleep-specialist note as part of prior authorization.

The prescriber must hold an active Michigan controlled-substance license and an active DEA number at Schedule IV. Prescriptions must comply with Michigan Public Health Code Part 177, which requires a valid patient-provider relationship and prohibits prescribing controlled substances based on an internet questionnaire alone. A synchronous audio-video telehealth visit satisfies the patient-provider relationship requirement under both Michigan law and current DEA telemedicine rules. 7

Telehealth Dayvigo Prescriptions in Michigan: What Is Actually Allowed

Michigan permits synchronous telehealth prescribing of Schedule IV controlled substances by Michigan-licensed providers following the Ryan Haight Online Pharmacy Consumer Protection Act and the DEA's 2023 telemedicine flexibilities. A live, two-way audio-video consultation qualifies as a valid in-person equivalent under Michigan compiled law MCL 333.17751. 8

Practically, that means a Michigan patient who completes a synchronous video appointment with a Michigan-licensed clinician can receive a lemborexant prescription electronically transmitted to a retail or mail-order pharmacy in Michigan or elsewhere in the United States. Audio-only (phone-only) visits do not satisfy the federal standard for Schedule IV prescribing under current DEA rules. 9

Telehealth platforms offering this service in Michigan typically complete the following sequence: (1) an intake questionnaire covering sleep history, current medications, and comorbidities; (2) a synchronous video appointment lasting 20 to 30 minutes; (3) clinical review and electronic prescription transmission within 24 to 48 hours if appropriate; and (4) pharmacy dispensing with delivery in 2 to 5 business days. Total time from intake to first dose averages 3 to 7 business days. 10

The American Academy of Sleep Medicine 2021 position statement on telehealth states that "video-based telemedicine for sleep disorders is an effective and appropriate care delivery model" and supports prescribing of sleep medications through validated telehealth encounters. 11

Labs and Workup Needed Before Starting Dayvigo in Michigan

No specific laboratory panel is required before prescribing lemborexant. The FDA label does not mandate baseline bloodwork. 12 A clinical assessment is still essential: providers will screen for narcolepsy or cataplexy (DORAs are contraindicated if narcolepsy is present because blocking orexin in a patient with already-deficient orexin signaling may worsen cataplexy), severe hepatic impairment (Child-Pugh C, at which dose adjustment to 5 mg maximum is required), and current use of strong CYP3A inhibitors such as clarithromycin or itraconazole. 13

Providers may optionally order a basic metabolic panel or liver function tests if hepatic disease is suspected, and some clinicians request a urine drug screen before initiating any Schedule IV agent. A formal sleep study (polysomnography or home sleep apnea test) is not required to prescribe Dayvigo but may be ordered if obstructive sleep apnea is clinically suspected, since untreated moderate-to-severe OSA combined with a sedating agent carries aspiration and hypoxia risk. 14

The Insomnia Severity Index (ISI), a validated 7-item questionnaire, and the Pittsburgh Sleep Quality Index (PSQI) are commonly used to document baseline severity and track treatment response. 15

Dosing: What Michigan Patients Should Expect

The recommended starting dose is 5 mg taken orally no more than 30 minutes before bedtime, with at least 7 hours remaining before the planned wake time. If 5 mg is tolerated but insufficient after 7 days, the prescriber may increase to 10 mg. 16

Dose ceilings apply in specific populations:

• Older adults (age 65 and older): 5 mg maximum per dose
• Moderate hepatic impairment (Child-Pugh B): 5 mg maximum
• Severe hepatic impairment (Child-Pugh C): avoid use
• Concurrent moderate CYP3A inhibitor use: 5 mg maximum
• Concurrent strong CYP3A inhibitor: avoid lemborexant entirely

The drug should not be combined with other CNS depressants including opioids, alcohol, or benzodiazepines without explicit prescriber guidance. The FDA label includes a warning about complex sleep behaviors (sleepwalking, sleep-driving) and recommends immediate discontinuation if such behaviors occur. 17

SUNRISE-1 found next-day residual sleepiness measured by the Karolinska Sleepiness Scale was not significantly different from placebo at the 5 mg dose, and only modestly elevated at 10 mg (mean difference 0.5 points on a 9-point scale, P<0.05). 18 That finding matters for Michigan patients with commercial driver's licenses (CDL), who should discuss occupational safety with their provider before starting any sleep aid.

Michigan Insurance Coverage and Prior Authorization for Dayvigo

Michigan Medicaid (Medicaid Health Plans and Fee-for-Service) covers lemborexant with prior authorization. The standard PA criteria require documentation of a diagnosed insomnia disorder, a trial of at least one first-line behavioral or pharmacologic treatment that was inadequate or not tolerated, and a clinical note supporting the medical necessity of a DORA over a generic alternative. 19

Most Michigan commercial insurance plans (Blue Cross Blue Shield of Michigan, Priority Health, HAP, and McLaren Health Plan) list Dayvigo on formulary Tier 3 or Tier 4, with prior authorization required. The typical PA package includes:

1. Diagnosis of chronic insomnia disorder (ICD-10 G47.00 or G47.09)
2. Documentation that cognitive behavioral therapy for insomnia (CBT-I) was offered, attempted, or declined with reasoning
3. Trial and failure of or intolerance to at least one generic hypnotic (e.g., zolpidem, trazodone, or doxepin)
4. Prescriber attestation that narcolepsy has been ruled out

Copay assistance is available through the Eisai patient-assistance program for commercially insured patients. The Dayvigo Savings Card may reduce out-of-pocket cost to as low as $0 per 30-day supply for eligible commercially insured patients. Patients without insurance may pay $300 to $450 per 30-count supply at Michigan retail pharmacies as of 2025, depending on the dispensing pharmacy and applicable discount programs. 20

How to Transfer a Dayvigo Prescription to Michigan

A Schedule IV prescription issued in another U.S. state is generally valid for dispensing in Michigan, provided the prescription was written by a DEA-registered prescriber, contains all required elements under Michigan Public Health Code, and has not been filled previously (Schedule IV prescriptions may be transferred between pharmacies one time under DEA regulations, or multiple times if both pharmacies share a real-time electronic database). 21

Steps for a Michigan transfer:

1. Contact the Michigan pharmacy where you want to fill the prescription.
2. Provide the name and phone number of the originating out-of-state pharmacy.
3. The Michigan pharmacist will contact the originating pharmacy directly to execute the Schedule IV transfer.
4. If both pharmacies are part of the same chain (e.g., CVS, Walgreens, Rite Aid), the transfer occurs electronically and usually completes the same day.

A Michigan provider can also issue a new prescription at a telehealth visit without requiring access to the original prescription from another state.

503A Compounding of Lemborexant in Michigan

Michigan-licensed 503A compounding pharmacies may prepare individualized lemborexant formulations for patients with a valid prescription from a Michigan-licensed prescriber. 503A status means the pharmacy compounds on a per-patient basis following a prescription rather than in bulk. 22

Lemborexant is not on the FDA's 503B bulk drug substance list, so it is not available from large outsourcing facilities in mass quantities. However, individual 503A compounding for specific patient needs (e.g., alternative dose strengths or alternative dosage forms for patients with swallowing difficulties) is permitted when commercially manufactured Dayvigo tablets are not clinically appropriate. 23

Michigan patients should verify that the compounding pharmacy is licensed with the Michigan Board of Pharmacy before filling a compounded lemborexant prescription. The Michigan Department of Licensing and Regulatory Affairs (LARA) maintains an online license verification tool at michigan.gov/lara. 24

Dayvigo vs. Other Insomnia Options Available in Michigan

Michigan prescribers have several evidence-based options for chronic insomnia. Placing lemborexant in context helps patients understand why a provider might choose it over alternatives.

Suvorexant (Belsomra), the first FDA-approved DORA (2014), shares the dual orexin antagonism mechanism. A 2023 network meta-analysis of 154 randomized controlled trials (N=44,089) published in The Lancet found that lemborexant had the most favorable benefit-risk balance among pharmacologic insomnia treatments assessed, ranking highest for both efficacy and next-day functioning. 25

Zolpidem (Ambien), still the most prescribed sleep aid in the United States, acts on GABA-A receptors and carries higher risks of next-morning impairment, especially at the 10 mg dose and in women, whose slower zolpidem clearance led the FDA to mandate sex-specific dosing in 2013. 26

Doxepin 3 mg and 6 mg (Silenor), approved for sleep maintenance insomnia, is a reasonable low-cost generic option but does not address sleep-onset insomnia and carries anticholinergic risk in older adults. 27

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment recommended by the American College of Physicians, the American Academy of Sleep Medicine, and the Society of Behavioral Sleep Medicine. The AASM states: "We recommend that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults." 28 Lemborexant is generally positioned as a second-line pharmacologic option when CBT-I is insufficient, unavailable, or declined.

Getting Dayvigo Through HealthRX in Michigan

HealthRX provides synchronous telehealth consultations with Michigan-licensed clinicians who can evaluate insomnia and, where clinically appropriate, prescribe lemborexant. The appointment takes place via HIPAA-compliant video on any smartphone, tablet, or computer. Michigan state law does not require an in-person visit before a telehealth clinician prescribes a Schedule IV medication when a valid patient-provider relationship is established through live video. 29

After the visit, the prescription is sent electronically to the Michigan pharmacy of your choice or to HealthRX's partner mail-order pharmacy. Most Michigan patients receive their first supply within 3 to 5 business days.

HealthRX clinicians follow the AASM's 2017 clinical practice guidelines for the pharmacologic treatment of chronic insomnia, which support DORA use as an evidence-based pharmacologic option, and document all visits in a structured SOAP note available to the patient through the HealthRX portal. 30

Step-by-Step: How to Get Your First Dayvigo Prescription in Michigan

1. Complete the HealthRX online intake form covering your sleep history, current medications, and relevant medical history. This takes approximately 10 minutes.
2. Book a synchronous video appointment. Same-day and next-day slots are available for Michigan patients.
3. Attend the 20-to-30-minute video consultation. Your clinician will confirm your insomnia diagnosis, rule out contraindications, and discuss dose selection.
4. If lemborexant is appropriate, the electronic prescription is transmitted to your chosen Michigan pharmacy within 24 hours.
5. Pick up at a local pharmacy or request mail-order delivery. Expect 2 to 5 business days for mail-order.
6. Take 5 mg by mouth no more than 30 minutes before bed, with at least 7 hours remaining before your alarm.
7. Follow up with your HealthRX clinician at 4 weeks to assess response and tolerability. If response is partial at 5 mg, your clinician may increase the dose to 10 mg at that visit.

A 30-day supply at 5 mg (30 tablets) or 10 mg (30 tablets) covers the standard initial dispensing period. Refills for Schedule IV substances in Michigan are limited to 5 refills within 6 months of the date of issue, after which a new prescription is required. 31